John E. Leonard

1.5k total citations
41 papers, 1.0k citations indexed

About

John E. Leonard is a scholar working on Cellular and Molecular Neuroscience, Immunology and Molecular Biology. According to data from OpenAlex, John E. Leonard has authored 41 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Cellular and Molecular Neuroscience, 13 papers in Immunology and 10 papers in Molecular Biology. Recurrent topics in John E. Leonard's work include Axon Guidance and Neuronal Signaling (13 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Toxin Mechanisms and Immunotoxins (7 papers). John E. Leonard is often cited by papers focused on Axon Guidance and Neuronal Signaling (13 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Toxin Mechanisms and Immunotoxins (7 papers). John E. Leonard collaborates with scholars based in United States, Germany and United Kingdom. John E. Leonard's co-authors include Milton H. Saier, Franz S. Hover, Michael Kaess, Brendan Englot, Hordur Johannsson, Matthew J. Walter, Maurice Zauderer, Terrence L. Fisher, Nabil Hanna and Christine Reilly and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

John E. Leonard

41 papers receiving 944 citations

Peers

John E. Leonard

IMMUN

CMN

Yu Herng Tan Singapore

Xinhua Liu China

Baozhi Chen United States

Chang Luo China

Sergio de Frutos Spain

Katherine Liu United States

Yong Mao China

Lin Song China

Ming Sun United States

Rong Wen United States

Yu Herng Tan Singapore

John E. Leonard

505 ×1.8

174 ×0.8

IMMUN

147 ×0.7

166 ×1.0

47 ×0.3

CMN

Citations per year, relative to John E. Leonard John E. Leonard (= 1×) peers Yu Herng Tan

Countries citing papers authored by John E. Leonard

Since Specialization

Citations

This map shows the geographic impact of John E. Leonard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John E. Leonard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John E. Leonard more than expected).

Fields of papers citing papers by John E. Leonard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John E. Leonard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John E. Leonard. The network helps show where John E. Leonard may publish in the future.

Co-authorship network of co-authors of John E. Leonard

This figure shows the co-authorship network connecting the top 25 collaborators of John E. Leonard. A scholar is included among the top collaborators of John E. Leonard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John E. Leonard. John E. Leonard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fisher, Terrence L., Elizabeth E. Evans, Vikas Mishra, et al.. (2023). SEMA4D blocking antibody, pepinemab, is a novel potential treatment for neurodegenerative disease: Clinical proof of concept in Phase 2 HD study supports ongoing clinical development in Phase 1/2 AD study. Alzheimer s & Dementia. 19(S7). 1 indexed citations

Evans, Elizabeth E., Terrence L. Fisher, John E. Leonard, et al.. (2020). Evidence that semaphorin 4D is upregulated in neurons in Huntington’s and Alzheimer’s diseases: Effects of a SEMA4D blocking antibody on FDG‐PET in a clinical trial, and treatment rationale for its use in AD. Alzheimer s & Dementia. 16(S9). 7 indexed citations

Lesinski, Gregory B., Terrence L. Fisher, Elizabeth E. Evans, et al.. (2019). Abstract CT016: Integrated biomarker trials of VX15/2503 (pepinemab) in combination with checkpoint inhibitors in window of opportunity studies in solid tumors. Cancer Research. 79(13_Supplement). CT016–CT016. 2 indexed citations

Leonard, John E., Terrence L. Fisher, Laurie A. Winter, et al.. (2015). Nonclinical Safety Evaluation of VX15/2503, a Humanized IgG4 Anti-SEMA4D Antibody. Molecular Cancer Therapeutics. 14(4). 964–972. 31 indexed citations

Patnaik, Amita, Glen J. Weiss, John E. Leonard, et al.. (2015). Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors. Clinical Cancer Research. 22(4). 827–836. 50 indexed citations

Fisher, Terrence L., Christine Reilly, Laurie A. Winter, et al.. (2015). Generation and preclinical characterization of an antibody specific for SEMA4D. mAbs. 8(1). 150–162. 36 indexed citations

Fisher, Terrence L., Christine Reilly, Virginia Litwin, et al.. (2015). Saturation monitoring of VX15/2503, a novel semaphorin 4D‐specific antibody, in clinical trials. Cytometry Part B Clinical Cytometry. 90(2). 199–208. 22 indexed citations

Evans, Elizabeth E., Siwen Hu‐Lieskovan, Holm Bußler, et al.. (2015). Antibody blockade of semaphorin 4D breaks down barriers to enhance tumoricidal immune infiltration and supports rational immunotherapy combinations. Journal for ImmunoTherapy of Cancer. 3(S2). 3 indexed citations

Patnaik, Amita, Ramesh K. Ramanathan, Drew Rasco, et al.. (2014). Phase 1 study of VX15/2503, a humanized IgG4 anti-SEMA4D antibody, in advanced cancer patients (pts).. Journal of Clinical Oncology. 32(15_suppl). 3052–3052. 2 indexed citations

10.

Flinn, Ian W., Marshall T. Schreeder, Steven Coutré, et al.. (2011). A phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3‐kinase P110δ, in combination with anti-CD20 monoclonal antibody therapy and/or bendamustine in patients with previously treated B-cell malignancies.. Journal of Clinical Oncology. 29(15_suppl). 3064–3064. 18 indexed citations

11.

Moore, David C., Matthew R. Walter, Edwin Olson, et al.. (2009). Simultaneous local and global state estimation for robotic navigation. 3794–3799. 26 indexed citations

12.

Brams, Peter, Amelia Black, Eduardo A. Padlan, et al.. (2001). A humanized anti-human CD154 monoclonal antibody blocks CD154–CD40 mediated human B cell activation. International Immunopharmacology. 1(2). 277–294. 36 indexed citations

13.

Anderson, Darrell R., Nabil Hanna, John E. Leonard, et al.. (1997). A PrimatizedMAb to Human CD4 Causes Receptor Modulation, without Marked Reduction in CD4+T Cells in Chimpanzees:In Vitroandin VivoCharacterization of a MAb (IDEC-CE9.1) to Human CD4. Clinical Immunology and Immunopathology. 84(1). 73–84. 25 indexed citations

14.

Nickbarg, Elliot, et al.. (1995). Structural Characterization of the Recombinant P40 Heavy Chain Subunit Monomer and Homodimer of Murine IL-12. Bioorganic Chemistry. 23(4). 380–396. 7 indexed citations

15.

Feldweg, Anna M., et al.. (1993). A dominant sulfhydryl-containing protein in the outer membrane of Neisseria gonorrhoeae. Journal of Bacteriology. 175(4). 1173–1175. 4 indexed citations

16.

Leonard, John E., et al.. (1991). Assessment of ligand effects in intracellular trafficking of ricin A chain using anti-ricin hybridomas.. PubMed. 51(6). 1689–93. 9 indexed citations

17.

Leonard, John E., et al.. (1987). Monoclonal Antibodies to Purified Ricin A-Chain: Production and Properties. Hybridoma. 6(2). 135–149. 4 indexed citations

18.

Grenier, Frank C., Ian P. Hayward, Maria Novotny, John E. Leonard, & Milton H. Saier. (1985). Identification of the phosphocarrier protein enzyme IIIgut: essential component of the glucitol phosphotransferase system in Salmonella typhimurium. Journal of Bacteriology. 161(3). 1017–1022. 10 indexed citations

19.

Leonard, John E., et al.. (1985). Kinetics of protein synthesis inactivation in human T-lymphocytes by selective monoclonal antibody-ricin conjugates.. PubMed. 45(11 Pt 1). 5263–9. 34 indexed citations

20.

Dillman, Robert O., et al.. (1985). Athymic mouse model of a human T-cell tumor.. PubMed. 45(11 Pt 2). 5632–6. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact